4.6 Article

Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 5, Issue 9, Pages 1461-1466

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JTO.0b013e3181e392d7

Keywords

Mesothelioma; Mesothelin; SMRP; Diagnosis; Biomarkers

Funding

  1. National Health and Medical Research Council of Australia
  2. Insurance Commission of Western Australia

Ask authors/readers for more resources

Introduction: Malignant mesothelioma (MM) is an aggressive, uniformly fatal tumor usually caused by exposure to asbestos Soluble mesothelin has been intensively investigated in the serum as a biomarker for this disease As urine is less complex and less invasive to collect than serum and may be a more acceptable specimen for large-scale screening studies of asbestos-exposed individuals, we determined whether the sensitivity and specificity for MM could be improved by measuring soluble mesothelin in the urine Methods: Soluble mesothelin concentrations were determined using the MESOMARK(TM) assay in concurrent serum and urine samples from 70 patients with pleural mm 111 patients with asbestos-related lung or pleural disease. and 45 patients with benign nonasbestos-related lung and pleural disease Only patients with scrum creatinine levels within the normal range were included in the study Sensitivities were determined and receiver operator characteristic curves were generated to compare the diagnostic accuracy of mesothelin in the serum and urine Results: At a specificity of 95% relative to individuals with benign lung cm pleural disease, serum mesothelin had a sensitivity of 66% and area under the curve of 0 882, whereas urinary mesothelin corrected for urine creatinine concentration had a sensitivity of 53% and area under the curve of 0 787 Conclusions: The sensitivity of urinary mesothelin does not warrant the use of urine as a biomarker specimen for MM diagnosis

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Respiratory System

Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy

Y. C. Gary Lee, Jenette Creaney

RESPIROLOGY (2021)

Article Oncology

A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers

Alistair M. Cook, Alison McDonnell, Michael J. Millward, Jenette Creaney, Arman Hasani, Michelle McMullen, Tarek Meniawy, Bruce W. S. Robinson, Richard a Lake, Anna K. Nowak

Summary: The study aimed to determine optimal dosing and scheduling of cyclophosphamide alongside pemetrexed-based chemotherapy to deplete regulatory T-cells in mesothelioma or non-small-cell lung cancer patients. However, the results showed that the specific Treg depletion seen with single-agent cyclophosphamide was not observed during pemetrexed-based chemotherapy, indicating poor evidence for the use of cyclophosphamide as an immunotherapeutic in combination with chemotherapy. Additionally, some patients had to discontinue cyclophosphamide due to toxicity.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Review Oncology

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy

Linda Ye, Jenette Creaney, Alec Redwood, Bruce Robinson

Summary: Neoantigens are unique mutant peptides in tumors that can elicit T-cell-mediated immune responses and are potential targets for personalized cancer therapies. Immunotherapy based on neoantigens in lung cancer shows promising prospects and opportunities for clinical applications.

JOURNAL OF THORACIC ONCOLOGY (2021)

Article Oncology

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma

I. M. Dick, Y. C. G. Lee, H. M. Cheah, A. Miranda, B. W. S. Robinson, J. Creaney

Summary: This study demonstrates that pleural effusions rich in a range of soluble factors are associated with poor prognosis in mesothelioma patients. These findings will enhance our ability to prognosticate outcomes in mesothelioma patients.

CANCER BIOMARKERS (2022)

Article Cell Biology

Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology

Amber Louw, Y. C. Gary Lee, Nathan Acott, Jenette Creaney, Chris Vliet, Siaw Ming Chai

Summary: The study assessed the utility of BAP1 immunohistochemistry in fluid samples for diagnosing malignant pleural mesothelioma. Results showed that loss of BAP1 was highly specific for malignancy, aiding in the diagnosis.

CYTOPATHOLOGY (2022)

Article Oncology

Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology

Amber Louw, Chris van Vliet, Joanne Peverall, Shane Colkers, Nathan Acott, Jenette Creaney, Y. C. Gary Lee, Siaw Ming Chai

Summary: This study found that detectable abnormalities of BAP1 and CDKN2A were present in pleural fluid specimens before the development of mesothelioma, suggesting a possible cytological equivalent for mesothelioma in situ.

CANCER CYTOPATHOLOGY (2022)

Review Oncology

What's next in cancer immunotherapy?-The promise and challenges of neoantigen vaccination

Alec J. Redwood, Ian M. Dick, Jenette Creaney, Bruce W. S. Robinson

Summary: The process of tumorigenesis results in genetic changes in tumor cells that have potential to serve as tumor-specific immune targets when expressed. Neoantigen vaccines, harnessing this immunogenicity, have shown efficacy in preclinical models and are now in clinical trials. The challenges in the personalized neoantigen vaccine field include identifying targetable antigens and addressing preexisting immunosuppression, particularly T-cell exhaustion, for the development of effective cancer vaccines.

ONCOIMMUNOLOGY (2022)

Article Oncology

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Roe

Summary: This study aimed to evaluate the impact of tumor BAP1 status on survival prediction in patients with pleural mesothelioma receiving first-line combination chemotherapy. The study found that BAP1 loss was an independent predictor of survival, and patients with BAP1 loss had longer survival after chemotherapy.

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Genetics & Heredity

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Jenette Creaney, Ann-Marie Patch, Venkateswar Addala, Sophie A. Sneddon, Katia Nones, Ian M. Dick, Y. C. Gary Lee, Felicity Newell, Ebony J. Rouse, Marjan M. Naeini, Olga Kondrashova, Vanessa Lakis, Apostolos Nakas, David Waller, Annabel Sharkey, Pamela Mukhopadhyay, Stephen H. Kazakoff, Lambros T. Koufariotis, Aimee L. Davidson, Priya Ramarao-Milne, Oliver Holmes, Qinying Xu, Conrad Leonard, Scott Wood, Sean M. Grimmond, Raphael Bueno, Dean A. Fennell, John Pearson, Bruce W. Robinson, Nicola Waddell

Summary: This study analyzed the genomic and immune features of malignant pleural mesothelioma (MPM) samples and identified driver genes, mutational signatures, and the tumor immune environment associated with MPM. The findings suggest that accounting for genomic and immune microenvironment status may influence future therapeutic planning.

GENOME MEDICINE (2022)

Review Pharmacology & Pharmacy

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies

Bruce W. S. Robinson, Alec J. Redwood, Jenette Creaney

Summary: Researchers have used asbestos-induced mouse models of mesothelioma to study this rare and fatal tumor type. These models have led to significant advancements in mesothelioma treatment, including improved response rates through clinical trials. In the future, these mouse models will continue to play a key role in the success of mesothelioma immunotherapy.

FRONTIERS IN PHARMACOLOGY (2022)

Letter Oncology

Response to Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma

Oluf Dimitri Roe, Jenette Creaney

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels

P. Ramarao-Milne, O. Kondrashova, A. -M. Patch, K. Nones, L. T. Koufariotis, F. Newell, V. Addala, V. Lakis, O. Holmes, C. Leonard, S. Wood, Q. Xu, P. Mukhopadhyay, M. M. Naeini, D. Steinfort, J. P. Williamson, M. Bint, C. Pahoff, P. T. Nguyen, S. Twaddell, D. Arnold, C. Grainge, F. Basirzadeh, D. Fielding, A. J. Dalley, H. Chittoory, P. T. Simpson, L. G. Aoude, V. F. Bonazzi, K. Patel, A. P. Barbour, D. A. Fennell, B. W. Robinson, J. Creaney, G. Hollway, J. V. Pearson, N. Waddell

Summary: This study explored drug repurposing opportunities using the Cancer Genome Interpreter and whole-genome sequencing. The ability of different sequencing methods, including whole-exome sequencing and comprehensive sequencing panels, to detect actionable mutations, tumor mutation burden, and microsatellite instability was compared. The results revealed shared biomarkers among different solid tumor types, with comprehensive panels identifying the majority of actionable mutations and whole-genome sequencing detecting more candidate actionable mutations.

ESMO OPEN (2022)

Article Oncology

Immune marker expression of irradiated mesothelioma cell lines

Faith Chang, Synat Keam, Tracy Seymour Hoang, Jenette Creaney, Suki Gill, Anna K. Nowak, Martin Ebert, Alistair M. Cook

Summary: This study characterizes the dose- and time-dependent changes in immune marker expression of commonly studied mesothelioma cell lines following radiation, providing insights for future studies on optimal dosing and scheduling of combined radiotherapy and immune checkpoint inhibition for mesothelioma.

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

Computational immunogenomic approaches to predict response to cancer immunotherapies

Venkateswar Addala, Felicity Newell, John V. Pearson, Alec Redwood, Bruce W. Robinson, Jenette Creaney, Nicola Waddell

Summary: Cancer immunogenomics is an emerging field that combines genomics and immunology to better understand and improve cancer immunotherapy. The use of large-scale genomic collaborations and advanced sequencing techniques has allowed researchers to identify clinically actionable alterations and predictive biomarkers in various types of cancer. Computational approaches and machine learning algorithms have been developed to analyze sequencing data and provide clinically useful information. However, there is still a need to fully understand the potential and limitations of these approaches in improving patient outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Meeting Abstract Oncology

Prognostic significance of pleural effusion exhausted CD8+T cell subsets in non-small cell lung cancer and mesothelioma.

Linda Ye, Ian Dick, Peter Chiang, Tina Firth, Jenette Creaney, Bruce Ws Robinson, Alec Redwood

JOURNAL OF CLINICAL ONCOLOGY (2022)

No Data Available